Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants after fourth Vaccination or Tixagevimab and Cilgavimab Administration in Cancer Patients

With Dr. med. univ. Maximilian Mair, Medical University Vienna, Austria

Patients with cancer are at high risk for severe COVID-19 diseases and show impaired immune responses after vaccination. Specifically, levels of neutralizing antibodies against variants of concern, including Delta and Omicron, are lower in cancer patients.

Fourth vaccination dose or administration of monoclonal neutralizing antibodies, such as tixagevimab and cilgavimab, is being considered, although data supporting this strategy are limited, especially for currently circulating variants, such as BA.4.

The Medical University Vienna analyzed the variant-specific humoral immunity after active and passive SARS-CoV-2 immunization in 72 patients with haemato-oncological diseases by comparing antibody levels after the third and fourth vaccinations or administration of tixagevimab and cilgavimab in patients with cancer.

Presenter: Maximilian Mair
Moderator: Zoi D. Pana
Organizor: VACCELERATE (Coordinator: Prof. Oliver A. Cornely)

DOI: 10.4126/FRL01-006435250.

свернуть